Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

Pharmaceutical medicine - 1 Nov 2025

Kong Leping, Grobman Ben, Mansur Arian, Lee Adele, Bondarchuk Connor, Erdogan Hannah, Lu Christine Y

Abstract excerpt

Tissue-agnostic therapies, which target molecular alterations across cancer types, have been approved by the US Food and Drug Administration (FDA) since 2017. These approvals were based on clinical trials enrolling patients across diverse tumor types, regardless of the tumor's site of origin. This analysis evaluated the efficacy and safety of FDA-approved tissue-agnostic therapies in patients with lung cancer,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRAF gene
Share to RET gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to United States

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 41032240
DOI: 10.1007/s40290-025-00582-x
PMCID: PMC12534342

Genes

BRAF
RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.PMID 41032240Read ↗

[The application of target-based tissue-agnostic therapy in the treatment of lung cancer].Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Lung Cancer: Targeted Therapy in 2025Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.Semantic proximity Read ↗

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2Semantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Rare molecular subtypes of lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.